MGMT and glioblastoma: Clinically, MGMT promoter methylation correlates with increased sensitivity to TMZ and longer overall survival, particularly in secondary glioblastomas where methylation is more prevalent (∼ 75 %) compared to primary glioblastomas (∼ 36 %) (MGMT, 2025).